Is pemetinib/pemetinib included in the scope of medical insurance reimbursement?

Pemigatinib/Pemigatinib (Pemigatinib), as a new type of targeted drug, has significant efficacy and safety in the treatment of cholangiocarcinoma. However, due to its high price, economic cost has become an important factor in considering whether to include it in the scope of medical insurance reimbursement.

The most important goals of patient treatment with pemetinib are to achieve disease control, delay symptom exacerbation, maintain health-related quality of life (HRQoL), delay disease progression, and prolong survival. It is also important that the drug has an acceptable safety profile. The convenient oral route of administration of pemetinib will help improve patients' quality of life compared with alternative treatment options, and it is reasonable to consider pemetinib in advance for patients who are considered unsuitable for standard first-line chemotherapy. However, patients with impaired hepatic function or severe hyperbilirubinemia are least suitable for treatment with pemetinib.

According to current understanding, pemetinib has been marketed in China, but has not yet been fully included in the national medical insurance. This means that although it performs well in terms of efficacy and safety, due to its higher economic cost, health insurance policymakers may need to make a trade-off between protecting patient interests and controlling medical costs. However, it is worth noting that medical insurance policy is a dynamic process. With the advancement of medical technology and adjustments to medical insurance policies, whether pemetinib will be included in the scope of medical insurance reimbursement in the future, as well as the specific reimbursement ratio, may change.

In addition, medical insurance policies may differ in different regions. Some places may formulate different medical insurance reimbursement policies based on their own financial situation, medical needs, drug costs and other factors. Therefore, regarding whether pemetinib is included in the scope of medical insurance reimbursement and the specific reimbursement ratio, patients and medical institutions should pay attention to local medical insurance policy trends in order to understand relevant information in a timely manner.